Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

Georgiana Dobri, Soamsiri Niwattisaiwong, James F. Bena, Manjula Gupta, John Kirwan, Lawrence Kennedy, Amir Hamrahian

Research output: Contribution to journalArticle

Abstract

Purpose: The growth hormone (GH) nadir during oral glucose tolerance test (OGTT) is the gold standard diagnostic test for acromegaly. The utility of OGTT-GH suppression test in patients with abnormal glucose metabolism (AGM) has not been well established. In this study, we compared the GH nadir during OGTT in patients evaluated for acromegaly in the presence and absence of AGM. Methods: This is a retrospective cohort study of patients with acromegaly (G1, n = 40) and a group in whom acromegaly was not confirmed (G2, n = 53) who had OGTT-GH suppression test during 2000–2012, using a monoclonal GH immunoenzymatic assay. The patients were categorized as having normal glucose metabolism (NGM) or AGM. GH nadir during OGTT in each group were compared. Results: In G1 and G2, 17 and 19 patients had AGM, respectively. Among 17 patients with diabetes, median HbA1C was 7% (range 5.7–9.6%). All except one patient had HbA1C< 8%. There was no difference in the GH nadir in patients with or without AGM within G1 (p = 0.15) and G2 (p = 0.43). All G1 patients with AGM had GH nadir > 0.4 µg/L. Four G1 patients with NGM had GH nadir<0.4 µg/L. All G2 patients had GH nadir < 0.4 µg/L, except one with NGM and GH nadir of 0.4 µg/L. Conclusion: Using highly sensitive GH assay, a GH nadir ≥ 0.4 µg/L during the OGTT-GH suppression test may be used for diagnosis of acromegaly in patients with AGM in the absence of poorly controlled diabetes.

Original languageEnglish (US)
JournalEndocrine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Acromegaly
Glucose Tolerance Test
Growth Hormone
Glucose
Routine Diagnostic Tests
Cohort Studies
Retrospective Studies

Keywords

  • Acromegaly
  • Diabetes
  • Diagnosis
  • Growth hormone nadir
  • OGTT

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism? / Dobri, Georgiana; Niwattisaiwong, Soamsiri; Bena, James F.; Gupta, Manjula; Kirwan, John; Kennedy, Lawrence; Hamrahian, Amir.

In: Endocrine, 01.01.2018.

Research output: Contribution to journalArticle

Dobri, Georgiana ; Niwattisaiwong, Soamsiri ; Bena, James F. ; Gupta, Manjula ; Kirwan, John ; Kennedy, Lawrence ; Hamrahian, Amir. / Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?. In: Endocrine. 2018.
@article{bf4bf8bb6c23469f8a536415274d714f,
title = "Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?",
abstract = "Purpose: The growth hormone (GH) nadir during oral glucose tolerance test (OGTT) is the gold standard diagnostic test for acromegaly. The utility of OGTT-GH suppression test in patients with abnormal glucose metabolism (AGM) has not been well established. In this study, we compared the GH nadir during OGTT in patients evaluated for acromegaly in the presence and absence of AGM. Methods: This is a retrospective cohort study of patients with acromegaly (G1, n = 40) and a group in whom acromegaly was not confirmed (G2, n = 53) who had OGTT-GH suppression test during 2000–2012, using a monoclonal GH immunoenzymatic assay. The patients were categorized as having normal glucose metabolism (NGM) or AGM. GH nadir during OGTT in each group were compared. Results: In G1 and G2, 17 and 19 patients had AGM, respectively. Among 17 patients with diabetes, median HbA1C was 7{\%} (range 5.7–9.6{\%}). All except one patient had HbA1C< 8{\%}. There was no difference in the GH nadir in patients with or without AGM within G1 (p = 0.15) and G2 (p = 0.43). All G1 patients with AGM had GH nadir > 0.4 µg/L. Four G1 patients with NGM had GH nadir<0.4 µg/L. All G2 patients had GH nadir < 0.4 µg/L, except one with NGM and GH nadir of 0.4 µg/L. Conclusion: Using highly sensitive GH assay, a GH nadir ≥ 0.4 µg/L during the OGTT-GH suppression test may be used for diagnosis of acromegaly in patients with AGM in the absence of poorly controlled diabetes.",
keywords = "Acromegaly, Diabetes, Diagnosis, Growth hormone nadir, OGTT",
author = "Georgiana Dobri and Soamsiri Niwattisaiwong and Bena, {James F.} and Manjula Gupta and John Kirwan and Lawrence Kennedy and Amir Hamrahian",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12020-018-1805-z",
language = "English (US)",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press",

}

TY - JOUR

T1 - Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

AU - Dobri, Georgiana

AU - Niwattisaiwong, Soamsiri

AU - Bena, James F.

AU - Gupta, Manjula

AU - Kirwan, John

AU - Kennedy, Lawrence

AU - Hamrahian, Amir

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: The growth hormone (GH) nadir during oral glucose tolerance test (OGTT) is the gold standard diagnostic test for acromegaly. The utility of OGTT-GH suppression test in patients with abnormal glucose metabolism (AGM) has not been well established. In this study, we compared the GH nadir during OGTT in patients evaluated for acromegaly in the presence and absence of AGM. Methods: This is a retrospective cohort study of patients with acromegaly (G1, n = 40) and a group in whom acromegaly was not confirmed (G2, n = 53) who had OGTT-GH suppression test during 2000–2012, using a monoclonal GH immunoenzymatic assay. The patients were categorized as having normal glucose metabolism (NGM) or AGM. GH nadir during OGTT in each group were compared. Results: In G1 and G2, 17 and 19 patients had AGM, respectively. Among 17 patients with diabetes, median HbA1C was 7% (range 5.7–9.6%). All except one patient had HbA1C< 8%. There was no difference in the GH nadir in patients with or without AGM within G1 (p = 0.15) and G2 (p = 0.43). All G1 patients with AGM had GH nadir > 0.4 µg/L. Four G1 patients with NGM had GH nadir<0.4 µg/L. All G2 patients had GH nadir < 0.4 µg/L, except one with NGM and GH nadir of 0.4 µg/L. Conclusion: Using highly sensitive GH assay, a GH nadir ≥ 0.4 µg/L during the OGTT-GH suppression test may be used for diagnosis of acromegaly in patients with AGM in the absence of poorly controlled diabetes.

AB - Purpose: The growth hormone (GH) nadir during oral glucose tolerance test (OGTT) is the gold standard diagnostic test for acromegaly. The utility of OGTT-GH suppression test in patients with abnormal glucose metabolism (AGM) has not been well established. In this study, we compared the GH nadir during OGTT in patients evaluated for acromegaly in the presence and absence of AGM. Methods: This is a retrospective cohort study of patients with acromegaly (G1, n = 40) and a group in whom acromegaly was not confirmed (G2, n = 53) who had OGTT-GH suppression test during 2000–2012, using a monoclonal GH immunoenzymatic assay. The patients were categorized as having normal glucose metabolism (NGM) or AGM. GH nadir during OGTT in each group were compared. Results: In G1 and G2, 17 and 19 patients had AGM, respectively. Among 17 patients with diabetes, median HbA1C was 7% (range 5.7–9.6%). All except one patient had HbA1C< 8%. There was no difference in the GH nadir in patients with or without AGM within G1 (p = 0.15) and G2 (p = 0.43). All G1 patients with AGM had GH nadir > 0.4 µg/L. Four G1 patients with NGM had GH nadir<0.4 µg/L. All G2 patients had GH nadir < 0.4 µg/L, except one with NGM and GH nadir of 0.4 µg/L. Conclusion: Using highly sensitive GH assay, a GH nadir ≥ 0.4 µg/L during the OGTT-GH suppression test may be used for diagnosis of acromegaly in patients with AGM in the absence of poorly controlled diabetes.

KW - Acromegaly

KW - Diabetes

KW - Diagnosis

KW - Growth hormone nadir

KW - OGTT

UR - http://www.scopus.com/inward/record.url?scp=85056316151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056316151&partnerID=8YFLogxK

U2 - 10.1007/s12020-018-1805-z

DO - 10.1007/s12020-018-1805-z

M3 - Article

C2 - 30415402

AN - SCOPUS:85056316151

JO - Endocrine

JF - Endocrine

SN - 1355-008X

ER -